ArticleScientific reports2026
Integrating single-cell and bulk transcriptomic analyses to explore key lactylation-related genes in benign prostatic hyperplasia.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Benign prostatic hyperplasia (BPH) is a prevalent age-related disorder characterized by chronic inflammation, metabolic dysregulation, and abnormal cellular proliferation. Protein lactylation, an emerging post-translational modification closely associated with cellular metabolism, has been implicated in the pathogenesis of various diseases. However, its role and associated molecular features in BPH remain uncharacterized. We integrated publicly available single-cell RNA sequencing (scRNA-seq) and bulk RNA-seq datasets derived from BPH and normal prostate tissues. Utilizing machine learning algorithms (LASSO, Random Forest, and Boruta) strictly as feature selection tools, we identified key lactylation-related candidate genes. Subsequently, employing the BPH-1 cell line in vitro, we preliminarily investigated the potential biological functions of the prioritized epithelial target, ANXA2, through siRNA-mediated knockdown, Western blotting, ELISA, and cell proliferation assays. We computationally identified ANXA2 and IFI27 as key lactylation-related candidate genes, both of which were significantly downregulated in BPH tissues. scRNA-seq data revealed their cell-type specificity, demonstrating that ANXA2 is predominantly expressed in epithelial cells, whereas IFI27 is primarily expressed in endothelial cells. Furthermore, we uncovered a potential link between metabolism and inflammation involving ANXA2. Specifically, ANXA2 knockdown in BPH-1 cells was associated with alterations in glycolytic gene expression and a concomitant reduction in lactate production. Our data suggest that this decreased lactate level is associated with elevated secretion of the proinflammatory cytokine IL-6 and enhanced cellular proliferation. Additionally, cellular trajectory and communication analyses indicated that ANXA2⁺ epithelial cells and IFI27⁺ endothelial cells represent distinct subpopulations characterized by enhanced intercellular signaling capacities, suggesting their potential roles as critical molecular hubs within the BPH microenvironment. This study presents the first single-cell resolution landscape of lactylation-related gene activity in BPH. We computationally identified ANXA2 and IFI27 as key lactylation-related candidate genes. Importantly, our study suggests a potential link whereby ANXA2 deficiency is associated with BPH cell proliferation and potential metabolic and inflammatory alterations. These findings provide valuable new insights into the underlying pathophysiological mechanisms of BPH and lay the groundwork for the development of targeted therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.